Funding agencies: The study was supported by Lundbeck A/S, Denmark.
Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia
Article first published online: 11 FEB 2014
© 2014 International Parkinson and Movement Disorder Society
Volume 29, Issue 7, pages 935–939, June 2014
How to Cite
Boesch, S., Nachbauer, W., Mariotti, C., Sacca, F., Filla, A., Klockgether, T., Klopstock, T., Schöls, L., Jacobi, H., Büchner, B., vom Hagen, J. M., Nanetti, L. and Manicom, K. (2014), Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia. Mov. Disord., 29: 935–939. doi: 10.1002/mds.25836
Relevant conflicts of interest/financial disclosures: The study was supported by Lundbeck A/S, Denmark. Sylvia Boesch received remuneration for consultative and advisory services. Caterina Mariotti, Alessandro Filla, Thomas Klockgether, Thomas Klopstock, and Ludger Schöls received honoraria for consultancy. Karen Manicom is an employee Lundbeck A/S, Denmark.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 12 JUN 2014
- Article first published online: 11 FEB 2014
- Manuscript Accepted: 9 DEC 2013
- Manuscript Revised: 12 NOV 2013
- Manuscript Received: 10 SEP 2013
Additional supporting information may be found in the online version of this article at the publisher's website.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.